Home ›
Leukemia Trials ›
NCT07936266
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.
Trial Details
NCT ID NCT07936266
Phase PHASE1
Sponsor Sunil G. Iyer
Status RECRUITING
Cancer Type Leukemia
Interventions Asciminib Inotuzumab ozogamicin
Locations (sample) Miami, Florida, United States|25.77427,-80.19366 Chicago, Illinois, United States|41.85003,-87.65005 New York, New York, United States|40.71427,-74.00597 Seattle, Washington, United States|47.60621,-122.33207
Key Eligibility Criteria
Documented and confirmed CD22+ R/R Ph+ B-ALL according to the World Health Organization (WHO) classification Relapsed ALL is defined as the detection of ≥ 5% blasts in the bone marrow with or without non-central nervous system (CNS) extramedullary disease Refractory ALL is defined as the failure to obtain a CRc after at least two courses of intensive induction or immunotherapy such as blinatumomab, o… Disease must be positive for Ph (p190 or p210 transcript) by cytogenetics or PCR
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →